Clinical Trial Update: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating tumor infiltrating lymphocytes (TIL) immunotherapy for metastatic melanoma has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Tumor Infiltrating Lymphocytes (TIL) Immunotherapy (tumor-infiltrating lymphocytes)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2023-01-18